Literature DB >> 15991277

Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer.

Guang-Yi Wang1, Bai Ji, Xu Wang, Jian-Hua Gu.   

Abstract

AIM: To observe the anti-cancer effect of iNOS selective inhibitor (aminoguanidine, AG) and investigate the relationship between iNOS inhibitor and angiogenesis, infiltration or metastasis in MFC gastric cancer xenografts.
METHODS: Fifty athymic mice xenograft models were established by inoculating gastric cancer cell MFC subcutaneously. Twenty-four hours later, 0.9% sodium chloride solution, mitomycin, low dosage AG, high dosage AG, mitomycin and AG were administered by intraperitoneal injection respectively. Thus these mice were divided into five groups of 10 each randomly: control group, MMC group, AG(L) group, AG(H) group, MMC+AG(H) group. Two weeks later the mice were killed, and the tumor weight, inhibitory rate were evaluated. Greiss assay was used to detect the nitric oxide levels in plasma. HE and immunohistochemistry staining were used to examine microvessel density (MVD) and the expression of iNOS, VEGF, and PCNA. Apoptosis was detected by using TUNEL assay.
RESULTS: The inhibitory rates in MMC+AG(H) group and AG(H) group were 52.9% and 47.1% respectively, which is significant statistically compared with that of control group (0). In treatment groups, the cell proliferation index (PI) was lower and apoptosis index was higher than those of control group. Microvessel density, iNOS, and VEGF in MMC+ AG(H) group were 8.8+/-2.6, 2.4+/-1.1, and 2.1+/-1.4 respectively, which is significant statistically compared with those of control group (68.3+/-10.6, 11.3+/-1.3, and 10.3+/-1.6). The NO level in plasma of MMC+ AGH and AG(H) group were 12.7+/-2.1 and 12.9+/-2.0 mumol/L. Compared with that of control group (46.6+/-2.3 mumol/L), the difference is statistically significant.
CONCLUSION: AG has anticancer effect on gastric cancer, and it has positive synergistic effect with chemotherapeutic drugs. It may play important inhibitory roles in angiogenesis of gastric cancer. The anticancer effect of iNOS inhibitors may include inducing cell apoptosis, suppressing cell proliferation and reducing angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15991277      PMCID: PMC4504880          DOI: 10.3748/wjg.v11.i25.3830

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Differential expression of nitric oxide synthase in human stomach cancer.

Authors:  E Koh; S H Noh; Y D Lee; H Y Lee; J W Han; H W Lee; S Hong
Journal:  Cancer Lett       Date:  1999-11-15       Impact factor: 8.679

2.  Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer.

Authors:  O Gallo; E Masini; L Morbidelli; A Franchi; I Fini-Storchi; W A Vergari; M Ziche
Journal:  J Natl Cancer Inst       Date:  1998-04-15       Impact factor: 13.506

3.  5-Fluorouracil inhibits nitric oxide production through the inactivation of IkappaB kinase in stomach cancer cells.

Authors:  In Duk Jung; So Young Yang; Chang Gyo Park; Kyung Bok Lee; Jong Seung Kim; Seok Yong Lee; Jeung Whan Han; Hyang Woo Lee; Hoi Young Lee
Journal:  Biochem Pharmacol       Date:  2002-11-15       Impact factor: 5.858

4.  Antiapoptotic role of endogenous nitric oxide in human melanoma cells.

Authors:  O Salvucci; M Carsana; I Bersani; G Tragni; A Anichini
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

Review 5.  Role of nitric oxide in tumor progression: lessons from experimental tumors.

Authors:  P K Lala; A Orucevic
Journal:  Cancer Metastasis Rev       Date:  1998-03       Impact factor: 9.264

6.  Chronic blockade of nitric oxide biosynthesis in rats: effect on leukocyte endothelial interaction and on leukocyte recruitment.

Authors:  S H P Farsky; P Borelli; R A Fock; S Z Proto; J M C Ferreira; S B V Mello
Journal:  Inflamm Res       Date:  2004-09       Impact factor: 4.575

7.  Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients.

Authors:  J C Lee; N H Chow; S T Wang; S M Huang
Journal:  Eur J Cancer       Date:  2000-04       Impact factor: 9.162

8.  Up-regulation of inducible nitric oxide synthase in Helicobacter pylori-associated gastritis may represent an increased risk factor to develop gastric carcinoma of the intestinal type.

Authors:  Gabriele Rieder; Johannes A Hofmann; Rudolf A Hatz; Manfred Stolte; Georg A Enders
Journal:  Int J Med Microbiol       Date:  2003-12       Impact factor: 3.473

Review 9.  Cellular and physiological effects of arginine.

Authors:  Betty C Tong; Adrian Barbul
Journal:  Mini Rev Med Chem       Date:  2004-10       Impact factor: 3.862

10.  Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features.

Authors:  Chang Wei Feng; Li Dong Wang; Lian Hua Jiao; Bin Liu; Shu Zheng; Xin Ji Xie
Journal:  BMC Cancer       Date:  2002-04-29       Impact factor: 4.430

View more
  12 in total

1.  Differential expression of apoptosis related proteins and nitric oxide synthases in Epstein Barr associated gastric carcinomas.

Authors:  Maria D Begnami; Andre L Montagnini; Andre L Vettore; Sueli Nonogaki; Mariana Brait; Alex Y Simoes-Sato; Andrea Q A Seixas; Fernando A Soares
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

2.  Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.

Authors:  Andrew G Sikora; Alexander Gelbard; Michael A Davies; Daisuke Sano; Suhendan Ekmekcioglu; John Kwon; Yared Hailemichael; Padmini Jayaraman; Jeffrey N Myers; Elizabeth A Grimm; Willem W Overwijk
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

3.  Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.

Authors:  Alexander L Rakhmilevich; Mark J Baldeshwiler; Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Nicholas A Kalogriopoulos; David S Koslov; Nico Van Rooijen; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-03-06       Impact factor: 6.968

4.  COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line.

Authors:  Yaghub Pazhang; Shahin Ahmadian; Nader Javadifar; Mahshid Shafiezadeh
Journal:  Tumour Biol       Date:  2011-11-15

5.  Potential involvement of nitric oxide synthase but not inducible nitric oxide synthase in the development of experimental corneal neovascularization.

Authors:  Yuan Chen; Gao-Qin Liu; Pei-Rong Lu
Journal:  Int J Ophthalmol       Date:  2011-08-18       Impact factor: 1.779

6.  Berberine-induced apoptosis via decreasing the survivin protein in K562 cell line.

Authors:  Yaghub Pazhang; Shahin Ahmadian; Massoud Mahmoudian; Mahshid Shafiezadeh
Journal:  Med Oncol       Date:  2010-06-02       Impact factor: 3.064

7.  Aminoguanidine impedes human pancreatic tumor growth and metastasis development in nude mice.

Authors:  Nora A Mohamad; Graciela P Cricco; Lorena A Sambuco; Máximo Croci; Vanina A Medina; Alicia S Gutiérrez; Rosa M Bergoc; Elena S Rivera; Gabriela A Martín
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

8.  Effects of quercetin on hyper-proliferation of gastric mucosal cells in rats treated with chronic oral ethanol through the reactive oxygen species-nitric oxide pathway.

Authors:  Jing-Li Liu; Jun Du; Ling-Ling Fan; Xiao-Yan Liu; Luo Gu; Ying-Bin Ge
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

Review 9.  Gasotransmitters in cancer: from pathophysiology to experimental therapy.

Authors:  Csaba Szabo
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

Review 10.  iNOS-selective inhibitors for cancer prevention: promise and progress.

Authors:  Naveena B Janakiram; Chinthalapally V Rao
Journal:  Future Med Chem       Date:  2012-11       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.